PL2632927T3 - Boroniany jako inhibitory arginazy - Google Patents

Boroniany jako inhibitory arginazy

Info

Publication number
PL2632927T3
PL2632927T3 PL11779904.9T PL11779904T PL2632927T3 PL 2632927 T3 PL2632927 T3 PL 2632927T3 PL 11779904 T PL11779904 T PL 11779904T PL 2632927 T3 PL2632927 T3 PL 2632927T3
Authority
PL
Poland
Prior art keywords
boronates
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
PL11779904.9T
Other languages
English (en)
Inventor
Zandt Michael Van
Jr. Gunnar Erik Jagdmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2632927T3 publication Critical patent/PL2632927T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
PL11779904.9T 2010-10-26 2011-10-19 Boroniany jako inhibitory arginazy PL2632927T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40676010P 2010-10-26 2010-10-26

Publications (1)

Publication Number Publication Date
PL2632927T3 true PL2632927T3 (pl) 2016-09-30

Family

ID=44913403

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11779904.9T PL2632927T3 (pl) 2010-10-26 2011-10-19 Boroniany jako inhibitory arginazy

Country Status (19)

Country Link
US (5) US9233985B2 (pl)
EP (3) EP3034509B1 (pl)
JP (1) JP5909239B2 (pl)
CN (2) CN103249737B (pl)
AU (1) AU2011320732B2 (pl)
BR (1) BR112013010099B1 (pl)
CA (1) CA2815536C (pl)
DK (1) DK2632927T3 (pl)
ES (2) ES2794006T3 (pl)
HK (2) HK1223104A1 (pl)
HR (1) HRP20160305T1 (pl)
HU (1) HUE027317T2 (pl)
IL (1) IL225926A (pl)
MX (1) MX336381B (pl)
PL (1) PL2632927T3 (pl)
RS (1) RS54750B1 (pl)
SI (1) SI2632927T1 (pl)
SM (1) SMT201600141B (pl)
WO (1) WO2012058065A1 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
CN103180328B (zh) 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
EP2852598B3 (en) * 2012-04-18 2016-10-19 Mars, Incorporated Ring constrained analogs as arginase inhibitors
EA201591003A1 (ru) 2013-01-04 2015-12-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US11624093B2 (en) 2014-04-24 2023-04-11 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
HUE046836T2 (hu) 2014-05-05 2020-03-30 Rempex Pharmaceuticals Inc Boronát sók szintézise és alkalmazásuk
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2016149393A1 (en) * 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2990192A1 (en) * 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108368176B (zh) 2015-10-01 2022-06-07 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法
EP4011887A1 (en) * 2015-10-30 2022-06-15 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
KR20190104521A (ko) * 2016-11-08 2019-09-10 칼리테라 바이오사이언시즈, 인코포레이티드 아르기나제 억제제 병용 요법들
AU2017382405B2 (en) * 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
MA48626A (fr) 2017-05-12 2020-03-18 Calithera Biosciences Inc Procédé de préparation de (3r,4s)-3-acétamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその合成
WO2019120296A1 (en) * 2017-12-22 2019-06-27 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as arginase inhibitors
JOP20200197A1 (ar) 2018-02-17 2020-08-16 Astrazeneca Ab مثبطات أرجيناز وطرق لاستخدامها
MX2020009290A (es) * 2018-03-05 2020-09-28 Arcus Biosciences Inc Inhibidores de la arginasa.
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CA3094939A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
CN111770756B (zh) * 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
WO2019218904A1 (zh) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020102646A2 (en) * 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20220056051A1 (en) * 2018-12-18 2022-02-24 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP3917936A4 (en) * 2019-02-06 2022-12-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. ALKYBORONIC ACIDS AS ARGINASE INHIBITORS
MA56324B1 (fr) * 2019-02-08 2023-10-31 Astrazeneca Ab 151 85 Soedertaelje Inhibiteurs de l'arginase et leurs procédés d'utilisation
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme Llc ARGINASE INHIBITORS AND METHODS OF USE
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11780840B2 (en) 2020-07-02 2023-10-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
WO2023283332A1 (en) * 2021-07-07 2023-01-12 Emory University Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions
WO2023191116A2 (en) 2022-01-21 2023-10-05 Opiyo Sammy Oyoo Improved suramin methods and compositions
US20230295124A1 (en) 2022-03-17 2023-09-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009890A (en) 1911-02-09 1911-11-28 Michael F Brauer Dumping attachment for headers.
US1006597A (en) 1911-05-26 1911-10-24 Rail Joint Co Insulated rail-joint.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
ATE250923T1 (de) 1997-07-29 2003-10-15 Alcon Lab Inc Galaktomannanpolymere und borat enthaltende augenarzneimittel
WO1999019295A1 (en) * 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20090298912A1 (en) 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
US20100056480A1 (en) 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
US20100189544A1 (en) 2007-07-12 2010-07-29 Sanyo Denki Co., Ltd. Counter-rotating axial-flow fan
AU2008312006B2 (en) 2007-10-12 2013-12-12 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxyliptin compounds for the treatment of ophthalmic conditions
WO2009137378A2 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
SI2389352T1 (sl) 2009-01-26 2019-08-30 The Trustees Of The University Of Pennsylvania, Center For Technology Transfer Inhibitorji arginaze in postopki uporabe
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
RS54750B1 (sr) 2010-10-26 2016-10-31 Mars Inc Borati kao inhibitori arginaze
CN110123820B (zh) 2010-12-31 2022-05-31 阿斯利康公司 精氨酸酶抑制剂及其使用方法
US9266908B2 (en) 2011-10-19 2016-02-23 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
EP2852598B3 (en) 2012-04-18 2016-10-19 Mars, Incorporated Ring constrained analogs as arginase inhibitors
CN111329989A (zh) 2012-11-02 2020-06-26 药品循环有限责任公司 Tec家族激酶抑制剂辅助疗法
EP3016932B1 (en) 2013-07-01 2019-02-27 Bristol-Myers Squibb Company Ido inhibitors
BR112016009200A8 (pt) 2013-10-25 2020-03-24 Pharmacyclics Llc uso de um inibidor de btk e um inibidor imune do ponto de verificação
CN105879030A (zh) 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US20180078515A1 (en) 2015-03-20 2018-03-22 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
CA2990192A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
EP4011887A1 (en) 2015-10-30 2022-06-15 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
MA48626A (fr) 2017-05-12 2020-03-18 Calithera Biosciences Inc Procédé de préparation de (3r,4s)-3-acétamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide

Also Published As

Publication number Publication date
CN106008569B (zh) 2020-04-03
MX2013004491A (es) 2013-11-04
BR112013010099A2 (pt) 2016-09-06
WO2012058065A1 (en) 2012-05-03
CN103249737B (zh) 2016-06-08
MX336381B (es) 2016-01-18
HUE027317T2 (en) 2016-10-28
US20150191492A1 (en) 2015-07-09
JP2013542223A (ja) 2013-11-21
HK1223104A1 (zh) 2017-07-21
DK2632927T3 (en) 2016-04-11
EP3034509A1 (en) 2016-06-22
US10098902B2 (en) 2018-10-16
BR112013010099B1 (pt) 2021-08-10
EP2632927B1 (en) 2016-02-10
US9233985B2 (en) 2016-01-12
US11389464B2 (en) 2022-07-19
US10603330B2 (en) 2020-03-31
IL225926A0 (en) 2013-06-27
US20170000808A1 (en) 2017-01-05
SI2632927T1 (sl) 2016-08-31
EP3719024A1 (en) 2020-10-07
CA2815536A1 (en) 2012-05-03
US20120129806A1 (en) 2012-05-24
HK1225390A1 (zh) 2017-09-08
ES2568680T3 (es) 2016-05-03
EP3034509B1 (en) 2020-04-22
SMT201600141B (it) 2016-07-01
EP2632927A1 (en) 2013-09-04
AU2011320732A1 (en) 2013-11-21
IL225926A (en) 2016-09-29
HRP20160305T1 (hr) 2016-07-01
CA2815536C (en) 2019-10-01
US20190054101A1 (en) 2019-02-21
CN106008569B9 (zh) 2020-05-22
AU2011320732B2 (en) 2018-07-05
ES2794006T3 (es) 2020-11-17
JP5909239B2 (ja) 2016-04-26
US9440995B2 (en) 2016-09-13
CN106008569A (zh) 2016-10-12
RS54750B1 (sr) 2016-10-31
US20200246362A1 (en) 2020-08-06
CN103249737A (zh) 2013-08-14

Similar Documents

Publication Publication Date Title
PL2632927T3 (pl) Boroniany jako inhibitory arginazy
HRP20151115T1 (en) Neprilysin inhibitors
HK1200371A1 (en) Neprilysin inhibitors
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
ZA201304208B (en) Neprilysin inhibitors
GB201004179D0 (en) Enzyme inhibitors
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2688568A4 (en) CYCLOPROPYLAMINES AS INHIBITORS OF LSD1
EP2584903A4 (en) NEW HETEROCYCLIC COMPOUNDS AS ERK HEMMER
GB201004178D0 (en) Enzyme inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
ZA201206456B (en) Uses of dgati inhibitors
EP2568812A4 (en) NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
EP2571359A4 (en) NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
ZA201303360B (en) Kat ii inhibitors
EP2632268A4 (en) NEW CONNECTIONS AS ERK HEMMER
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
EP2579716A4 (en) NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
EP2571855A4 (en) NEW PROLYLCARBOXYPEPTIDASE INHIBITORS
EP2563379A4 (en) SOX9 INHIBITORS
HK1187611A1 (en) Kat ii inhibitors kat ii
EP2579873A4 (en) NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
PL2558462T3 (pl) Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
GB201006605D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors